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Circulating tumor cells (CTCs) represent a surrogate biomarker of hematogenous metastases and thus could be
considered as a ‘liquid biopsy’ which reveals metastasis in action. But it is absolutely a challenge to detect CTCs due to
their extreme rarity. At present, the most common principle is to take advantage of the epithelial surface markers of
CTCs which attach to a specific antibody. Antibody-magnetic nanobeads combine with the epithelial surface
markers, and then the compound is processed by washing, separation, and detection. However, a proportion of
CTC antigen expressions are down-regulated or lost in the process of epithelial-mesenchymal transition (EMT),
and thus, this part of CTCs cannot be detected by classical detection methods such as CellSearch. To resolve this
problem, some multiple-marker CTC detections have been developed rapidly. Additionally, nanotechnology is a
promising approach to kill CTCs with high efficiency. Implantable nanotubes coated with apoptosis-promoting
molecules improve the disease-free survival and overall survival. The review introduces some novel CTC detection
techniques and therapeutic methods by virtue of nanotechnology to provide a better knowledge of the progress
about CTC study.
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Introduction
Circulating tumor cells (CTCs) are shed from primary
tumors, enter the circulatory system, and migrate to dis-
tant organs to form metastases that ultimately lead to
the death of most cancer patients [1]. It is of great im-
portance to carry out further study on CTCs because
tumor is the major cause of human beings' death and
approximately 90% of death is caused by the secondary
tumor [2-4].
Thomas Ashworth firstly proposed the hypothesis of
CTCs in 1869 [5], but studies on CTCs have made little
progress in the last century mainly due to the limited
condition to detect the CTCs. It is a challenging job to
detect the CTCs in the peripheral blood since the CTCs
are extremely scarce (just a few CTCs mixed with the
approximately 10 million leukocytes and 5 billion erythro-
cytes in 1 ml of blood) [6]. The current studies indicate
that there is a close relationship between CTC enumer-
ation and the severity of disease and clinical prognosis,* Correspondence: zhouyuan851@163.com
Department of Surgery, Shanghai Jiao Tong University Affiliated Sixth
People's Hospital, Shanghai 200233, China
© 2014 Gao and Yuan; licensee Springer. This i
Attribution License (http://creativecommons.or
in any medium, provided the original work is pthus initiating further studies. The CTC number has been
established as a helpful prognostic biomarker of malignant
epithelial tumor including breast cancer [7,8], prostate
cancer [9,10], and colon cancer [11]. With the relative
technology developed rapidly, the achievements about
CTCs are fruitful in the last decade.
The metastatic process is comprised of the following
steps: neoangiogenesis, intravasation, circulation in the
peripheral blood, extravasation, and ultimately resulting
in colonization and growth at distant sites [12,13]. Obvi-
ously, CTCs act as the ‘vector’ of metastasis, and the
successful capture and analysis of the CTCs throw light
on the nature of the primary tumor and characterization
of the secondary tumor. However, tumor cells in circula-
tion are heterogeneous. On the one hand, they can exist
in the circulatory system in various forms, such as sim-
ple cells, clumps of tumor cells, association with blood
cells, and non-viable cells, so the CTCs are only a part of
the tumor cells in circulation and other forms of tumor
cells can also form metastasis [14]. On the other hand,
during invasion and metastasis in epithelial tumors,
epithelial-mesenchymal transition (EMT), a phenotypic
change in epithelial cells may occur. Tumor cells lose thes an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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chymal phenotype in the process of EMT, which facilitates
their invasion through the vascular endothelium and mi-
gration into the circulation. Then CTCs extravasate out of
the circulation and invade into tissues to ultimately
form a metastasis, and the reverse progress is called
mesenchymal-epithelial transition (MET). The epithe-
lial surface markers alter during the process of EMT
and MET, so antibody-based methods will lose some
malignant tumor cells [14,15]. In addition, there is no
single epithelial marker which is expressed in all tumor
cells. Although the epithelial cellular adhesion molecule
(EpCAM) is the most used tumor surface biomarker in
the detection of CTCs, it is not necessarily expressed in
all types of epithelial tumor. Furthermore, EpCAM may
be lost in the process of EMT, so some CTCs can be
missed by CellSearch. Thus, we should take the above
properties into account when applying new technolo-
gies to detect and manipulate the CTCs. Therefore,
simultaneous staining with multiple epithelial markers
or negative staining with leukocyte markers is the fu-
ture trend to detect CTCs.
Nanotechnology, the manipulation of matter on an
atomic, molecular, or supramolecular scale, is expected to
show great capability for the early detection, accurate diag-
nosis, and personalized treatment of malignant tumors.
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ease diagnosis and treatment drastically [16,17]. Many
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nanotechnology, for example, CellSearch System [18],
AdnaSystem [19], versatile immunomagnetic nanocar-
rier platform [20], one-step detection method [21],
aptamer application [22], and magnetophoresis technol-
ogy [23] (Table 1). Nanoscale devices have several ad-
vantages over other devices: high sensitivity, microsize,
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medicine.
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the cellular and genetic levels. Lastly, powerful analytical
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of relative oncogenes and anti-oncogenes. Classical de-
tection methods usually carry out the three stages in
sequence, and nanoparticles prove to be a powerful tool in
the process of CTC detection. Herein, nanotechnology
will show its special property and function in the following
nanoscale devices during the process of CTC detection.
The application of nanotechnology in CTC detection
CellSearch System
CellSearch System, the current gold standard of CTC de-
tection, is the only detective method approved by the US
Food and Drug Administration (FDA) [18,25,26]. The
CTC enumeration determined by CellSearch System pre-
dicts the disease-free survival (DFS) and overall survival
(OS) in patients with breast cancer, colorectal cancer, and
prostate cancer in multicenter studies, and it proves to be
an independent predictive factor [7,11,27,28].
Although CellSearch System is the gold standard to de-
tect CTCs, many limitations still exist yet. In 131 different
histological tumor types and subtypes, 33.6% of CTCs
have low or positive expression of EpCAM. Only 81% of
adenocarcinomas of the colon, 78% of pancreas cancer,
and 71% of hormone-refractory adenocarcinomas of the
prostate have positive EpCAM expression [29]. Some
tumor lines lose the expression of cytokeratins (CK8,
CK18, and CK19) during metastasis [30]. Besides, during
the treatment of cancer, if normal epithelial cells fall into
the peripheral blood, they will mix up with CTCs and it
will be difficult to identify them. In addition, the fact that
many tumor cells with high-grade malignancy lose surface
antigens during epithelial-mesenchymal transition (EMT)
indicates that the detection of the antigen of epithelial
cells may miss the most malignant tumor cells [6,15,31].
Furthermore, the separated CTCs undergoing centrifuga-
tion and permeabilization cannot be cultured and studied
further during the process.
The amount of CTCs is also a limiting factor. The
CTCs are so rare that 7.5 ml of blood sample of the total
5 l in an adult may not completely reflect the entire
tumor cell population. More blood sample means higher
positive detection. Of course, it is not a proper way to
improve the sensitivity. Notably, the FDA-cleared Cell-
Search System may underestimate the number of CTCs;
an investigative CellSearch Profile approach could nearly
detect a 30-fold higher number of CTCs by using the
same paired blood samples [32]. As more accurate and
sensitive methods are developed, the CTCs can be tested
with less blood sample and shorter turnaround time (a
30-min window is preferred) [33]. The current Cell-
Search System still cannot meet the need for a point-of-
care test since the CTC assignment process is not
operated as simple and automatic as the pregnancy test
and diabetes test. As a new diagnostic method, theclinical significance of screening CTCs needs to be vali-
dated and more evidence should be accumulated to form
the acknowledged guidelines and diagnosis criterion
[24,34].
Therefore, application to routine clinical practice is
still controversial. Many constitutions and guidelines are
conservative to the application of the CTC enumeration,
so more evidences should be collected to validate its
utility in tumor diagnosis and treatment [35]. To over-
come the limitations of CellSearch System, many new
devices have been developed, although most of those are
still in the experimental stage.AdnaSystem
Due to the rarity of the CTCs in the peripheral blood, the
detection technique must show high sensitivity, and re-
verse transcription polymerase chain reaction (RT-PCR)
provides that sensitivity and feasibility [36]. AdnaTest
BreastCancerSelect/Detect (AdnaGen AG, Langenhagen,
Germany) is a new device to detect CTCs. The AdnaTest
can detect as few as one tumor cell in 1 ml of mouse
blood in a blood spiking experiment [37]. Human breast
cancer cells are pre-enriched firstly by immunological
nanobeads functionalized with three different antibodies,
then the separated cells are lysed, and PCR is performed
for HER2, MUC1, and GA733-2. Similarly, PCR for
GA733-2, CEA, and epidermal growth factor receptor
(EGFR) is performed to diagnose colon cancer and PCR
for PSMA, PSA, and EGFR to diagnose prostate cancer
[19,38]. Although the AdnaTest has equivalent sensitivity
to that of CellSearch System in detecting two or more
CTCs, it has several advantages over the latter [38]. Firstly,
after recognition of tumor-associated markers, the isolated
mRNA from CTCs can further be used for high-
throughput gene expression profiling. Secondly, isolation
and detection of stem cell and EMT markers can be real-
ized. Thirdly, the CTC selection process and detection
process could be used separately and may decrease the
cost of detection of CTCs. However, we should put the
shortcomings in mind: on the one hand, the AdnaTest is
liable to present false-positive due to marker expression
on non-tumor cells; on the other hand, enumeration of
CTCs is not likely to undertake.Versatile immunomagnetic nanocarrier platform
The biomarkers of CTCs have changed during EMT, for
example, EpCAM might be down-regulated and expres-
sion of vimentin is present, so EpCAM-based methods
miss some CTCs [39]. Supposing more useful markers
are applied to detect the CTCs, the capture efficiency
would be improved significantly. Deng et al. report that
the assay method combining CK and EpCAM detects
15% to 111% more CTCs than the CellSearch™ method
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7.5 ml of blood) [40].
The immunomagnetic nanocarrier platform is a nano-
particle with a gold shell and iron oxide core (Figure 1)
[20]. The gold shell is coated with PEG-SH and a hetero-
functional linker conjugated with a specific antibody dir-
ectly. After adding magnetic nanobeads labeled with
anti-EpCAM, anti-HER2, anti-EGFR, and anti-CK anti-
bodies into different cell lines, the cell surface markers are
identified by dark-field microscopy. The CTC capture effi-
ciency is improved by combining microliquid technology
to make full use of the intracellular and extracellular bio-
markers. In a tumor cell spiking experiment, peripheral
blood from healthy volunteers and a certain amount of
CTCs are mixed up, and then the sample is passed
through a microfluidic chamber at a continuous rate of
2.5 ml/h in the magnetic field and then identified using
fluorescent staining. Notably, the CTC capture efficiency
is 70% to 80% by using a nanoparticle coated with anti-CK
antibody similar to the FDA-approved CellSearch System.
But the CTC capture efficiency can be enhanced by utiliz-
ing two different nanoparticles. In addition, the combined
tests improve the capture efficiency of EpCAM-low
expressed cells. In this way, the EpCAM-low expressed
cells are detected efficiently. The immunomagnetic nano-
carrier platform captures CTCs efficiently, enumerates
CTCs accurately, and analyzes the surface molecules in
detail. The process eliminates multiple preprocessing steps
such as plasma replacement, centrifugation, and sample
transfer between tubes which are commonly used in other
assays, for example, the CellSearch method. Thus, the
simple and efficient platform is a promising CTC detec-
tion method.
Recently, Lee et al. demonstrate capture, in situ protein
expression analysis, and cellular phenotype identification
of CTCs simultaneously by using hybrid nanoparticles
(HNPs) [41]. Each HNP constitutes three parts: antibodies
that bind specifically to a known biomarker for CTCs, aFigure 1 Schematic of an antibody molecule combined with immuno
platform. Left: schematic of an antibody molecule combined with an imm
and an iron oxide core. The surface is functionalized with a heterofunction
(PEG-SH) which are used to link the antibody and the nanoparticle. Right: a
capturing CTCs. (Adapted from [20]).quantum dot that emits fluorescence signals, and bio-
tinylated DNA which is bound with streptavidin-coated
quantum dots. They test three different breast cancer
subtypes, and the average capture efficiency of CTCs is
87.5% with an identification accuracy of 92.4%. Subse-
quently, captured cells are released at efficiencies of 86.1%
by cleaving the DNA portion with a restriction enzyme.
Further study indicates that the released cells are viable
and proliferative in vitro. The method has several advan-
tages: it could efficiently capture heterogeneous CTCs, in-
cluding those with low EpCAM expression; the progress
without organic dye could not kill CTCs; and the ‘inter-
ested’ cells are selectively released and then cultured
in vitro, enabling additional studies possible, such as drug
screening and gene analysis. Although the above two
methods seem to be perfect for capturing and analyzing
CTCs, there is still a long way to apply the new technology
to routine clinical practice.
Rapid detection method
During a series of processes, such as erythrocyte lysis,
cell centrifugation, and washing, many CTCs get lost
and much detection time and money are spent, so it is a
trend to study rapid detection. Kim et al. [21] report a
rapid one-step method to detect ovarian cancer CTCs.
They develop a fluorescent nanoprobe with enhanced
fluorescent intensity (magnetic NP [MNP]-SiO2 [rhoda-
mine B isothiocyanate (RITC)]) and then combine it
with the MUC1 monoclonal antibody. The compound is
added into the sample directly, and after washing and
fixation, approximately 107 cells are analyzed in the
FCM. The number of cells with a positive signal indica-
tive of OVCAR-3 cells is counted as 23, 32, 58, and 387
for the unspiked blood samples and the indirect blood
models with 100, 1,000, and 10,000 OVCAR-3 cells, re-
spectively. This method needs no enrichment and fewer
washing, and it also detects CTCs rapidly and feasibly.
But the method should be validated via clinical trials.magnetic particle and versatile immunomagnetic nanocarrier
unomagnetic particle. The nanoparticle is composed of a gold shell
al linker and polyethylene glycol terminated with dithiol group
versatile immunomagnetic nanocarrier platform in microfluidics for
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tion is limited too much; if more specific monoclonal
antibodies are attached to the magnetic nanoparticles,
the result will be more satisfying.
Micro-nuclear magnetic resonance (μNMR) is a novel
method to detect circulating tumor cells; it consists of
solenoidal microcoils, a portable permanent magnet, and
custom-built NMR hardware. The measurement time is
typically less than 30 min; the detection starts with cell
separation, fixation, and pretreatment; then cells are in-
cubated with monoclonal antibodies against the protein
of interest coated with TCO-NHS (trans-cyclooctene),
and then are reacted with synthesized Tz-MNP (mag-
netic nanoparticles); and finally, the sample is located in
the coil to get detected [42]. The sensitivity and specifi-
city of ovarian cancer and lung cancer diagnosis are
more than 90% by means of a quadruple marker subset
(MUC1 + EGFR +HER2 + EpCAM) (Figure 2) [43,44].
The quad marker detection of cancer cells in blood is
much more sensitive than conventional EpCAM-based
detection. The use of μNMR technology for direct mea-
surements of rare CTCs in whole blood is quite creative,
and the preclinical validation of a quadruple CTC
marker signature harbors promising clinical utility. The
key question is whether the CTC levels and characters
would be beneficial to the clinical decision.
Aptamer-associated detection strategy
Aptamers are single-stranded DNA or RNA oligonucleo-
tides that bind to target molecules with robust binding
affinities. They are generated though repeated rounds of
processes termed systematic evolution of ligands by ex-
ponential enrichment (SELEX) and bind to a wide range
of target molecules, including extracellular ligands and
cell surface proteins, small interfering RNAs (siRNAs),
chemotherapeutic agents, cell toxins, and nanoparticles
[45]. Moreover, man-made aptamers possess several ad-
vantages over natural-made antibodies. The man-madeFigure 2 Schematic of the quad-μNMR system. After being incubated w
μNMR device and the sensitivity is improved significantly. (Adapted from [4aptamers can be generated rapidly and conveniently ac-
cording to various diagnostic and therapeutic needs and
can be stored with long-term stability as dry powder or
in solution and act with fast tissue penetration. These
chemical properties make aptamers ideal candidates as
probes for detection and targeted therapy and may re-
place the antibody in research, diagnostic methods, and
therapeutics [46].
Huang et al. design multiple aptamers conjugated on
Au-Ag nanorods, up to 80 fluorophore-labeled aptamers
attached on a 12 nm × 56 nm nanorod [47]. This leads
to an affinity at least 26-fold higher than the intrinsic af-
finity of the original aptamer probes, and the fluores-
cence signal increases by 300-fold compared with those
labeled by the individual aptamer probe. Researchers
have already designed a creative method to detect CTCs
without a fluorochrome by taking advantage of aptamer
technology [22]. Due to their plasmon resonance, when
the gold nanoparticles come into proximity with one an-
other, their absorption spectra and their scattering pro-
files change. Therefore, the color of aptamer-conjugated
gold nanoparticles (ACGNPs) bound with targeted cells
shifts while the unbound ACGNPs show no change, so
the bare eyes as well as a colorimetric assay identify the
color change and it is likely to be a very useful assay
technique for point-of-care diagnostics.
Besides, aptamers have a wide application in tumor
therapy. As aptamers are an excellent intermedium, they
combine various organic molecules to form chimeras,
for example, aptamer-antibody chimera, aptamer-protein
chimera, aptamer-siRNA chimera, and aptamer-miRNA
chimera and then combine with nanoparticle as a carrier
to be absorbed by the CTCs to perform pharmacological
action [46,48].
Magnetophoresis technology to separate CTCs
That the magnetic particle is drove to a certain direction
in the magnetic field is defined as magnetophoresis, andith four different mono-antibodies, the sample is spun down in the
3]).
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which is an efficient and high-throughput separation
technology in recent years [49,50]. It is an easy, rapid,
and accurate method to separate RNA and tumor cells
[51-53]. Herein, we introduce a novel CTC separation
device applying the lateral magnetophoresis principle de-
signed by Kim et al. [23]. The device is mainly fabricated
by two pieces of glass slides, and the core which consists
of a ferromagnetic permalloy wire array is hidden between
them. The device detects CTCs effectively and efficiently
since experimental results indicate that the CTC microse-
parator isolates approximately 90% of CTCs spiked into
blood samples with a flow rate of up to 5 ml/h and the
purity of separated CTCs is 97%; the overall isolation pro-
cedure can be completed within 15 min for 200 μL of per-
ipheral blood. Besides, clinical practice has demonstrated
that it can monitor the therapeutic effect and recurrence
of tumor.
The process is quite simple and only needs three steps:
buffer injection only, sample and buffer at the same flow
rate, and a second injection of buffer only. So the CTC
microseparator platform is easy to establish and automate.
The technology has many unique properties. Firstly, the
separation method maintains intactness and contributed
to further study about CTCs. Secondly, the simple proced-
ure reduces CTC loss during the enrichment process, im-
proving the sensitivity. Thirdly, the CTC microseparator
can be simply applied for the separation of various CTCs
by using other tumor-specific antibodies and changing the
size of the magnetic nanobeads to optimize the magnetic
force to detect specific tumor CTCs. As it can be com-
bined with other advanced genetic detection methods
(e.g., single-cell RT-PCR), it pushes the development of an
automated platform for CTC-based cellular and molecular
assays.
The application of nanotechnology in CTC therapy
Nanoparticles have many unique and excellent physical
properties, and we can take advantage of the properties
to overcome the limitations of traditional diagnostic
and therapeutic methods [54]. The nanoparticles
applied in tumor therapy currently include liposomes,
polymeric nanoparticles, protein nanoparticles, ceramic
nanoparticles, metallic nanoparticles, and carbon
nanotubes [55], but only a few are approved by the
FDA, such as pegylated liposomal doxorubicin (Doxil in
the USA and Caelyx outside the USA), liposomal
daunorubicin (DaunoXome), non-pegylated liposomal
doxorubicin (Myocet), and albumin-bound paclitaxel nano-
particles [56]. Faltas has already concluded some CTC
therapeutic methods, but many are still in the experimental
stage and there are many problems to be solved before be-
ing applied in routine clinical practice [57]. Herein, we
introduce some novel methods for CTC therapy.The nanoparticles and the halloysite nanotube fixed
on the substrate significantly increase the number of
combined selectin and tumor necrosis factor (TNF)-re-
lated apoptosis-inducing ligand (TRAIL), thus improving
the capture efficiency for targeting CTCs [58,59]. Besides,
TRAIL induces a death signal via the caspase pathway
[60,61]. There is no significant effect of TRAIL on
hematopoietic stem cells and other normal blood cells,
but it induces apoptosis in a wide variety of cancer cells.
Rana et al. design a capillary flow chamber by a bionic
method [62]. The surface of the flow capillary chamber is
functionalized with TRAIL and E-selectin and takes 1 h to
kill 30% of the captured cells, but in the static condition, it
will take 4 h to kill 30% of the cells. Different protein mol-
ecules could be applied in the device to capture various
CTCs to induce apoptosis; the same technology can be ap-
plied in clinical practice to capture rare cells in the periph-
eral blood. The technology applied in clinical practice will
significantly decrease the load of the disseminated tumor
cells in cancer patients.
Besides, the microtube flow device proves to kill CTCs
more efficiently if the specimen is pretreated with a par-
ticular drug. Clinical trials indicate that aspirin prevents
the occurrence of colorectal cancer [63-66]. Aspirin
treatment alone kills only about 3% of Colo205 cells
when compared to untreated control. When cells pre-
treated with aspirin are perfused through the microtube
flow device for 1 h and analyzed 18 h later, the kill rate
is 44.32% while perfusing untreated cells for 1 h shows a
kill rate of 17%. The kill rate of cells perfused through
the microtube following aspirin pretreatment for 1 h is
found to be similar to that of untreated cells perfused
over the combined surface for 2 h. This means that the
CTCs pretreated with aspirin can be killed more rapidly
and the microtube functionalized with TRAIL and E-
selectin can be combined with drugs to kill cancer cells
to reduce the cells more quickly and efficiently [67].
Another novel nanodevice has been developed to kill
CTCs. The strong absorbance of single-walled carbon
nanotubes (SWCNTs) in 700 to 1,100-nm near-infrared
(NIR) light can be used for optical stimulation of nano-
tubes inside living cells to afford various useful func-
tions. When the nanotubes are coated with folacin, they
can combine with tumor cells with folacin specially, and
then consistent NIR light radiation causes cell death
without harming receptor-free normal cells. So SWCNT
combined with specific chemical matter under NIR light
radiation is a novel way to convey drugs and treat tu-
mors [68,69]. Neves et al. [70] design a SWCNT-
annexin V (AV) conjugate by taking advantage of the
phenomenon that AV combines specially with the an-
ionic phospholipids expressed externally on the surface
of tumor cells and endothelial cells that line the tumor
vasculature. It kills most 4 T1 mouse mammary tumors
Gao and Yuan Nanoscale Research Letters 2014, 9:500 Page 7 of 10
http://www.nanoscalereslett.com/content/9/1/500for the majority of the animals by 11 days since the ir-
radiation is at a wavelength of 980 nm. The combination
of photothermal therapy with the immunoadjuvant cyclo-
phosphamide results in an increased survival rate. Also,
in vivo results suggest that the SWCNT-AV/NIR treat-
ment is a promising approach to treat cancer. Moreover,
Hossain et al. utilize iron oxide nanoparticles and bismuth
nanoparticles to combine the folate receptor and then kill
CTCs under X-ray radiation [71]. The systemic toxicity as-
sociated with conventional therapy may thus be signifi-
cantly reduced in targeted photodynamic therapy, but a
series of problems should be solved before entering clin-
ical practice, such as the toxicity of nanoparticles and how
to eliminate them in the body after use [72].
One new trend of manipulating CTCs is to kill CTCs
in vivo. Researchers have already developed a medical
device, functionalized structured medical wire (FSMW),
that offers opportunity of capturing CTCs from the cir-
culating blood of cancer patients (Figure 3) [73]. The de-
vice is based on a stainless steel medical wire of 0.5 mm
in diameter and 160 mm in length. The first 20 mm is
plated with a thick gold layer, and a synthetic polycar-
boxylate and anti-EpCAM are attached to the gold layer.
The EpCAM-functionalized FSMW surface dwells in the
lumen of the vein for 30 min, and the total volume of
blood that comes in contact with the FSMW is estimated
to be 1.5 to 3 l. The capture rate of CTCs is 10/12 for pa-
tients with breast cancer with a median of 5.5 CTCs and
12/12 for patients with non-small lung cell cancer
(NSCLC) with a median of 16 CTCs. As an in vivo device
to capture CTCs, it is very unique and paves the way for
future study. It is not only a way to capture CTCs but also
offers a potential therapeutic trend which will initiate ‘dia-
lysis therapy’ for cancer therapy just as dialysis therapy for
renal failure.
As the CTCs shed from the primary tumor inconstantly,
the blood samples extracted from the patients only
reflected a temporal condition [6]. In order to realize con-
sistent detection and treatment, the implantable vascularFigure 3 Schematic drawing of the functionalized tip of the FSMW. Th
blood for 30 min. (Adapted from [73]).shunt device is an ideal design. Wojciechowski et al. have
already used the device to capture CD34+ hematopoietic
stem and progenitor cells (HSPCs) [74]. Similarly, we can
design a vascular shunt to capture CTCs. The CTCs
should be captured firstly and then induce apoptosis to
decrease the CTC load and inhibit the tumor metastatic
progress. Then we capture specific CTCs by means of dif-
ferent molecules, such as CD44, CK, and E-selectin.
Apoptotic molecules including TRAIL [62,75], Fas-L
[76-78], TNF [79,80], and liposomes with encapsulated
siRNA [81] will make a difference in the kill of CTCs.
Scarberry et al. have demonstrated that targeted removal
of migratory tumor cells by functionalized magnetic nano-
particles impedes metastasis and tumor progression [82].
They mix the magnetic nanoparticles (MNPs) functional-
ized with ephrin-A1 mimetic peptides selective for the
EphA2 receptor with the peritoneal fluid withdrawn from
female C57BL/6 mice injected with a murine ovarian can-
cer cell line. Then the processed peritoneal fluid is re-
introduced into the peritoneal cavity. They found that
tumor progression of the experimental group is 10.77
times slower than that of the control group which receives
no intervention, and the median time to endpoint for the
experimental group (49 days) is 32.4% longer than that for
the control group (37 days), which indicates that the inter-
vention is quite efficient. We envision that the technology
could be applied to cancer patients. Firstly, the body liquid
(including blood and peritoneal fluid) is pumped out and
then mixes with the MNPs to discharge the malignant
cells; the purged liquid is then returned to the body. Once
the protocol is accomplished at a satisfying level, it shall
be an amazing breakthrough in tumor therapy.
Conclusions
At present, the most important applications of the CTC
technology are the monitoring of the CTC account of can-
cer patients and evaluation of the metastasis of malignant
tumor [6,7,83]. But the present devices are not ideal
enough to meet the application needs because thee gold-coated tip of the stainless steel captures CTCs in the circulating
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detection spectrum still need to be addressed. Manipulat-
ing CTCs in vivo directly is an attractive direction; it de-
notes that the process can reduce tumor metastasis and
even cut metastasis while dealing with the primary tumor,
and it also means that we should overcome some great
challenges: temporal heterogeneity of dissemination and
sample size limitations for in vivo techniques [25], so
much more effort should be paid to enhance the practical
application of CTCs. Nanotechnology has already been
studied a lot in CTCs, and it probably has a wider applica-
tion in tumor diagnosis and treatment. We can design a
long therapeutical guidewire by virtue of nanotechnology
and CTC theory which is placed in the vessel by means of
interventional methods. The surface of the guidewire is
covered with various kinds of nanoparticles decorated
with adhesion molecules and apoptosis-inducing ligands
for the capture and kill of CTCs. In order to realize per-
sonal therapy, the nanoparticles can be modified accord-
ing to the characteristics of the CTCs. The therapy
outcomes can be quantified by comparing the number of
CTCs before and after the process. If we keep the number
of CTCs at quite a low level, patients can survive longer
even if they live with tumor [7].
In a word, with the advent of translational medicine
and multiple-discipline treatment (MDT), the basic re-
search products about nanotechnology and CTCs are
supposed to offer a better guide for clinical decision.
Meanwhile, we should also pay attention on the side ef-
fects of nanotechnology while exploiting it. In the future,
the use of nanotechnology for CTC detection and kill is
promising, and it will offer a multifunctional, potable
platform in the field of anticancer therapy.
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